Zhu JK, Wang J. Cytochrome P450 3A gene family in gastric cancer: Unveiling diagnostic biomarkers and therapeutic targets for personalized treatment. World J Clin Oncol 2025; 16(4): 101548 [DOI: 10.5306/wjco.v16.i4.101548]
Corresponding Author of This Article
Jun-Kun Zhu, Department of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong 999077, China. 1155215781@link.cuhk.edu.hk
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Apr 24, 2025; 16(4): 101548 Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.101548
Cytochrome P450 3A gene family in gastric cancer: Unveiling diagnostic biomarkers and therapeutic targets for personalized treatment
Jun-Kun Zhu, Jing Wang
Jun-Kun Zhu, Department of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China
Jing Wang, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, Guangdong Province, China
Author contributions: Zhu JK was responsible for the conceptualization and formulation of the research objectives, and completed the majority of the original draft writing and figure creation, thereby making the primary contribution to the core content of the paper; Wang J supplemented the details of the initial draft (writing, review, and editing) and optimized the overall structure and format of the paper to ensure its logical coherence and readability; Zhu JK and Wang J jointly conducted a literature search and organization of resources, providing the necessary theoretical support for the writing of the paper; and all authors reviewed the final manuscript and agreed to its publication.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Kun Zhu, Department of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong 999077, China. 1155215781@link.cuhk.edu.hk
Received: September 18, 2024 Revised: January 12, 2025 Accepted: February 21, 2025 Published online: April 24, 2025 Processing time: 188 Days and 19.8 Hours
Abstract
The cytochrome P450 3A (CYP3A) gene family’s role in early progression of gastric cancer was comprehensively investigated. Its potential as a therapeutic target was evaluated. Upon literature review, aberrant expression of the CYP3A gene family has a strong correlation with gastric cancer onset, although the precise underlying mechanisms remain unclear. To assess its potential as a biomarker for early diagnosis and a therapeutic target, we have provided a comprehensive review of the regulatory mechanisms governing CYP3A gene family expression in gastric cancer, as well as its relation with early tumor progression and the tumor microenvironment. The CYP3A gene family is crucial in the proliferation, migration, and invasion of gastric cancer cells and promotes cancer progression by modulating inflammatory responses and oxidative stress within the tumor microenvironment. Furthermore, genetic polymorphisms in CYP3Aenzymes highlight its potential value in personalized medicine. Based on these findings, this paper explores the feasibility of developing inhibitors and activators targeting CYP3A enzymes and discusses potential applications in gene therapy. This research provides crucial theoretical support for the CYP3A gene family as an early diagnostic marker and therapeutic target for gastric cancer. In the future, multi-omics studies and large-scale clinical trials will be essential to advance clinical translation of these findings.
Core Tip: Although the role of cytochrome P450 3A (CYP3A) enzymes in gastric cancer remains underexplored, this review synthesizes existing evidence to reveal their involvement in tumor growth, migration, and resistance to chemotherapy. By integrating insights into CYP3A polymorphisms and their influence on drug metabolism, the study provides a potential framework for developing personalized treatment strategies aimed at improving patient outcomes.
